This focused issue on “Mechanisms of Resistance to EGFR-targeted Therapy” is edited by Dr. Trever Bivona, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
Dr. Bivona is a cell and molecular biologist and a board-certified medical oncologist. He received his MD and PhD degrees from NYU School of Medicine, followed by internal medicine training at the Brigham and Women’s Hospital/Harvard Medical School in Boston, and medical oncology and post-doctoral research training at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Bivona then joined the faculty at the University of California, San Francisco where he is currently an Associate Professor and directs a basic and translational research program investigating oncogene signaling pathways and the molecular basis of response and resistance to cancer therapeutics.
Focused issue outline:
- Introduction to this focused issue
Trever Bivona, University of California, San Francisco, CA, USA
- Mechanisms of resistance to osimertinib
Rafael Rosell, Germans Trias i Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain
- Acquired resistance
Jonathan Riess, UC Davis Comprehensive Cancer Center, Sacramento, USA
- Liquid biopsy
Hatim Hussain, UC San Diego Health - La Jolla, Moores Cancer Center, San Diego, USA
Collin Blakely, University of California, San Francisco, USA
- Tumor evolution
Caroline McCoach, University of California, San Francisco, USA
- Tumor microenvironment biology and therapeutic opportunities
Julia Rotow, University of California, San Francisco, USA